130 related articles for article (PubMed ID: 16039122)
21. Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.
Reger TS; Zunic J; Stock N; Wang B; Smith ND; Munoz B; Green MD; Gardner MF; James JP; Chen W; Alves K; Si Q; Treonze KM; Lingham RB; Mumford RA
Bioorg Med Chem Lett; 2010 Feb; 20(3):1173-6. PubMed ID: 20022493
[TBL] [Abstract][Full Text] [Related]
22. Efficient synthesis of 3-aminocyclobut-2-en-1-ones: squaramide surrogates as potent VLA-4 antagonists.
Brand S; de Candole BC; Brown JA
Org Lett; 2003 Jun; 5(13):2343-6. PubMed ID: 12816444
[TBL] [Abstract][Full Text] [Related]
23. 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers.
Vieira E; Huwyler J; Jolidon S; Knoflach F; Mutel V; Wichmann J
Bioorg Med Chem Lett; 2005 Oct; 15(20):4628-31. PubMed ID: 16099654
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4.
Okigami H; Takeshita K; Tajimi M; Komura H; Albers M; Lehmann TE; Rölle T; Bacon KB
Eur J Pharmacol; 2007 Mar; 559(2-3):202-9. PubMed ID: 17234179
[TBL] [Abstract][Full Text] [Related]
25. Highly potent, water soluble benzimidazole antagonist for activated alpha 4 beta 1 integrin.
Carpenter RD; Andrei M; Lau EY; Lightstone FC; Liu R; Lam KS; Kurth MJ
J Med Chem; 2007 Nov; 50(23):5863-7. PubMed ID: 17948981
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationship studies of a series of peptidomimetic ligands for alpha(4) beta(1) integrin on Jurkat T-leukemia cells.
Liu R; Peng L; Han H; Lam KS
Biopolymers; 2006; 84(6):595-604. PubMed ID: 17041919
[TBL] [Abstract][Full Text] [Related]
27. Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.
Doherty GA; Yang GX; Borges E; Chang LL; MacCoss M; Tong S; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Jun; 12(11):1501-5. PubMed ID: 12031329
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists.
Huryn DM; Ashwell S; Baudy R; Dressen DB; Gallaway W; Grant FS; Konradi A; Ley RW; Petusky S; Pleiss MA; Sarantakis D; Semko CM; Sherman MM; Tio C; Zhang L
Bioorg Med Chem Lett; 2004 Apr; 14(7):1651-4. PubMed ID: 15026043
[TBL] [Abstract][Full Text] [Related]
29. Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
La Motta C; Sartini S; Salerno S; Simorini F; Taliani S; Marini AM; Da Settimo F; Marinelli L; Limongelli V; Novellino E
J Med Chem; 2008 Jun; 51(11):3182-93. PubMed ID: 18452283
[TBL] [Abstract][Full Text] [Related]
30. Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines.
Ouyang X; Piatnitski EL; Pattaropong V; Chen X; He HY; Kiselyov AS; Velankar A; Kawakami J; Labelle M; Smith L; Lohman J; Lee SP; Malikzay A; Fleming J; Gerlak J; Wang Y; Rosler RL; Zhou K; Mitelman S; Camara M; Surguladze D; Doody JF; Tuma MC
Bioorg Med Chem Lett; 2006 Mar; 16(5):1191-6. PubMed ID: 16377187
[TBL] [Abstract][Full Text] [Related]
31. Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.
Setoguchi M; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Muro F; Iigo Y; Takayama G; Yokoyama M; Taira T; Aonuma M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2012 Feb; 20(3):1201-12. PubMed ID: 22261021
[TBL] [Abstract][Full Text] [Related]
32. N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.
Kamenecka TM; Lanza T; de Laszlo SE; Li B; McCauley ED; Van Riper G; Egger LA; Kidambi U; Mumford RA; Tong S; MacCoss M; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Aug; 12(16):2205-8. PubMed ID: 12127538
[TBL] [Abstract][Full Text] [Related]
33. Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.
Kopka IE; Lin LS; Mumford RA; Lanza T; Magriotis PA; Young D; DeLaszlo SE; MacCoss M; Mills SG; Van Riper G; McCauley E; Lyons K; Vincent S; Egger LA; Kidambi U; Stearns R; Colletti A; Teffera Y; Tong S; Owens K; Levorse D; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Sep; 12(17):2415-8. PubMed ID: 12161146
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
[TBL] [Abstract][Full Text] [Related]
35. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.
Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ
Bioorg Med Chem Lett; 2003 Mar; 13(5):805-8. PubMed ID: 12617895
[TBL] [Abstract][Full Text] [Related]
36. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
Kim JY; Seo HJ; Lee SH; Jung ME; Ahn K; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Jan; 19(1):142-5. PubMed ID: 19022666
[TBL] [Abstract][Full Text] [Related]
37. The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists.
Hagmann WK
Curr Top Med Chem; 2004; 4(14):1461-71. PubMed ID: 15544537
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antimicrobial studies of a new series of 2-[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]-5-substituted-1,3,4-oxadiazoles.
Gaonkar SL; Rai KM; Prabhuswamy B
Eur J Med Chem; 2006 Jul; 41(7):841-6. PubMed ID: 16616395
[TBL] [Abstract][Full Text] [Related]
39. N-Aroyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
Sidduri A; Tilley JW; Lou JP; Chen L; Kaplan G; Mennona F; Campbell R; Guthrie R; Huang TN; Rowan K; Schwinge V; Renzetti LM
Bioorg Med Chem Lett; 2002 Sep; 12(17):2479-82. PubMed ID: 12161162
[TBL] [Abstract][Full Text] [Related]
40. Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction).
Treonze KM; Alves K; Fischer P; Hagmann WK; Hora D; Kulick A; Vakerich K; Smith ND; Lingham RB; Maniar S; Reger TS; Zunic J; Munoz B; Prasit P; Nicholson D; Si Q; Judd K; Nicolich S; Kellerhouse P; Thompson D; Mumford RA
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):79-87. PubMed ID: 19250687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
